-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 27, pharmaceutical companies such as Zhejiang Medicine, ST Eye Medicine, Xingqi Eye Medicine, Kanghong Pharmaceutical, and Weiming Pharmaceutical released their 2021 annual report performance forecast.
Pharmaceuticals and Weiming Pharmaceuticals are expected to double their net profits, and Kanghong Pharmaceuticals and Weiming Pharmaceuticals are expected to increase their net profits by over 200%
.
Among them, Zhejiang Pharmaceutical released the 2021 annual report performance forecast.
It is expected to achieve a net profit of 959 million yuan to 1.
142 billion yuan from 2021-01-01 to 2021-12-31, an increase of 33.
68% to 59.
19%, and a net profit of 717 million yuan in the previous year.
Basic earnings per share were 0.
75 yuan
.
During the reporting period, affected by the epidemic, the prices of industrial raw materials rose, the production capacity of peer companies was limited, and the prices of the company's leading products rose; the company closely followed the changes in market supply and demand, overcame a series of difficulties such as the tight supply chain caused by the epidemic, optimized the industrial layout, and actively developed International and domestic markets, improve the industrial chain of competitive products, continue to promote cost reduction and efficiency enhancement, enhance the company's ability to control risks and respond to changes, and improve the quality of business operations
.
The performance forecast of ST Muyao’s 2021 annual report shows that the company expects a net profit of -37 million yuan to -30 million yuan in 2021, an increase of 8.
68% to 25.
96%, a net profit of -40.
518 million yuan in the same period last year, and a basic earnings per share of -0.
33 Yuan
.
The company stated that the parent company's pharmaceutical center was affected by the overall relocation this year, and the production and sales of some of the company's products were affected
.
The 2021 annual report performance forecast released by Xingqi Eye Medicine shows that it is expected to achieve a net profit of 187 million to 211 million yuan in 2021, an increase of 112.
46% to 140.
49%, and a net profit of 87.
9786 million yuan in the same period last year
.
Regarding the reasons for the growth in performance, the company stated that in 2021, the company will continue to increase market development efforts, optimize customer structure, consolidate core competitive advantages, continuously improve brand influence and product competitiveness, and achieve steady growth in the company's main business income.
The net profit of listed company shareholders rose simultaneously
.
Kanghong Pharmaceutical's 2021 annual report performance forecast shows that it is expected to achieve a net profit of 400 million to 520 million yuan in 2021, an increase of 248% to 293%, and a basic earnings per share of 0.
435 yuan to 0.
566 yuan
.
Net profit in the same period last year was -270 million yuan, and basic earnings per share was -0.
3074 yuan
.
The reasons for the turnaround in performance
.
The company is attributable to: During the reporting period, the company continued to optimize the method of academic promotion and maintained stable growth of its main business; the company continued to strengthen operation management, strengthen cost control, and improve management efficiency and effectiveness; the company included in the current profit and loss research and development expenses during the reporting period lower than the same period last year
.
Unnamed Medicine also released the 2021 annual report performance forecast today.
It is expected to achieve a net profit of 234 million to 352 million yuan from 2021-01-01 to 2021-12-31, an increase of 219.
73% to 279.
50%, and a basic earnings per share of 0.
3556 yuan to 0.
5331 yuan
.
Net profit in the same period last year was -196 million yuan, and basic earnings per share was -0.
2970 yuan
.
Regarding the changes in performance, the company stated that due to factors such as the recovery of the domestic economy, the sales volume of the company's main products, Enjingfu and Jiefu, increased year-on-year during the reporting period, and operating income increased.
magnitude increase
.
Pharmaceuticals and Weiming Pharmaceuticals are expected to double their net profits, and Kanghong Pharmaceuticals and Weiming Pharmaceuticals are expected to increase their net profits by over 200%
.
Among them, Zhejiang Pharmaceutical released the 2021 annual report performance forecast.
It is expected to achieve a net profit of 959 million yuan to 1.
142 billion yuan from 2021-01-01 to 2021-12-31, an increase of 33.
68% to 59.
19%, and a net profit of 717 million yuan in the previous year.
Basic earnings per share were 0.
75 yuan
.
During the reporting period, affected by the epidemic, the prices of industrial raw materials rose, the production capacity of peer companies was limited, and the prices of the company's leading products rose; the company closely followed the changes in market supply and demand, overcame a series of difficulties such as the tight supply chain caused by the epidemic, optimized the industrial layout, and actively developed International and domestic markets, improve the industrial chain of competitive products, continue to promote cost reduction and efficiency enhancement, enhance the company's ability to control risks and respond to changes, and improve the quality of business operations
.
The performance forecast of ST Muyao’s 2021 annual report shows that the company expects a net profit of -37 million yuan to -30 million yuan in 2021, an increase of 8.
68% to 25.
96%, a net profit of -40.
518 million yuan in the same period last year, and a basic earnings per share of -0.
33 Yuan
.
The company stated that the parent company's pharmaceutical center was affected by the overall relocation this year, and the production and sales of some of the company's products were affected
.
The 2021 annual report performance forecast released by Xingqi Eye Medicine shows that it is expected to achieve a net profit of 187 million to 211 million yuan in 2021, an increase of 112.
46% to 140.
49%, and a net profit of 87.
9786 million yuan in the same period last year
.
Regarding the reasons for the growth in performance, the company stated that in 2021, the company will continue to increase market development efforts, optimize customer structure, consolidate core competitive advantages, continuously improve brand influence and product competitiveness, and achieve steady growth in the company's main business income.
The net profit of listed company shareholders rose simultaneously
.
Kanghong Pharmaceutical's 2021 annual report performance forecast shows that it is expected to achieve a net profit of 400 million to 520 million yuan in 2021, an increase of 248% to 293%, and a basic earnings per share of 0.
435 yuan to 0.
566 yuan
.
Net profit in the same period last year was -270 million yuan, and basic earnings per share was -0.
3074 yuan
.
The reasons for the turnaround in performance
.
The company is attributable to: During the reporting period, the company continued to optimize the method of academic promotion and maintained stable growth of its main business; the company continued to strengthen operation management, strengthen cost control, and improve management efficiency and effectiveness; the company included in the current profit and loss research and development expenses during the reporting period lower than the same period last year
.
Unnamed Medicine also released the 2021 annual report performance forecast today.
It is expected to achieve a net profit of 234 million to 352 million yuan from 2021-01-01 to 2021-12-31, an increase of 219.
73% to 279.
50%, and a basic earnings per share of 0.
3556 yuan to 0.
5331 yuan
.
Net profit in the same period last year was -196 million yuan, and basic earnings per share was -0.
2970 yuan
.
Regarding the changes in performance, the company stated that due to factors such as the recovery of the domestic economy, the sales volume of the company's main products, Enjingfu and Jiefu, increased year-on-year during the reporting period, and operating income increased.
magnitude increase
.
